Effective only in tumors with wild-type TP53; ineffective in those with p53 loss or mutation; the primary dose-limiting toxicity is thrombocytopenia, driven by p53-mediated apoptosis of megakaryocytes (Fabbroni et al., 2024). The gene discussed is TP53; the disease is Thrombocytopenia.